Synairgen, Pharmaxis Pair Up On LOXL2 Lung Disease Therapy

UK biotechnology company Synairgen plc is teaming up with Australian pharmaceutical company Pharmaxis Ltd to develop a new drug for idiopathic pulmonary fibrosis (IPF) which it hopes to pair up with a big pharma on later down the line.